Tesamorelin

HIV-associated lipodystrophy (HAL) occurs in approximately 40–50% of HIV patients on long-term antiretroviral therapy (ART), particularly protease inhibitors. It is characterized by visceral fat accumulation (often with visible abdominal protrusion), subcutaneous fat wasting from the face and extremities, dyslipidemia, and insulin resistance. The visceral fat excess is associated with impaired growth hormone pulsatility—particularly reduced overnight GH peaks. Tesamorelin restores physiological GHRH pulsatility at the pituitary, generating endogenous GH pulses that preferentially mobilize visceral adipose tissue through lipolytic mechanisms. It does not directly address subcutaneous fat loss.

Tesamorelin is a GHRH (the hypothalamic hormone that tells the pituitary to make GH), not GH itself. It works upstream in the endocrine axis. This distinction matters clinically: Tesamorelin triggers natural pulsatile GH release governed by the pituitary's own feedback regulation, so GH levels rise appropriately without sustained supraphysiological peaks. Direct GH injection bypasses pituitary feedback entirely and produces persistent GH elevation. Tesamorelin does not suppress endogenous GH axis; discontinuation returns GH to baseline without suppression rebound. Safety profile: fewer growth-promoting side effects and no evidence of IGF-1 elevation beyond age-adjusted normal range.

Yes. Researchers at Massachusetts General Hospital and elsewhere have investigated Tesamorelin for: (1) Non-alcoholic fatty liver disease (NAFLD)—a 2018 Lancet HIV study showed 35% reduction in liver fat fraction; (2) Mild cognitive impairment (MCI)—a 2018 JAMA Neurology trial showed preserved functional connectivity and improved cognition in older adults with early MCI; (3) General visceral adiposity (non-HIV)—a 2017 JAMA Internal Medicine RCT showed significant visceral fat reduction in abdominally obese adults without HIV. These findings suggest applications well beyond the approved HIV lipodystrophy indication.

Common side effects in clinical trials include injection site reactions (~25%), fluid retention/edema (~10%), and arthralgia (~10%). Because it elevates IGF-1 (within normal range), it is contraindicated in patients with active malignancies due to theoretical IGF-1-mediated tumor growth promotion. It also cannot be used in patients with pituitary disorders that prevent GH response to GHRH. Visceral fat returns to baseline within 6 months of discontinuation, meaning continuous administration is required to maintain effects—a significant practical limitation.

Tesamorelin is unique because it has Phase 3 human clinical trial data and FDA approval—an evidence standard that separates it from most GH secretagogues in the research space. Unlike GHRP-based secretagogues (ipamorelin, GHRP-6, sermorelin), Tesamorelin's clinical evidence base comes from multiple large, randomized, placebo-controlled trials in well-characterized patient populations with CT-measured visceral fat as the primary outcome—not self-reported measures or surrogate markers. This makes its visceral fat reduction claims among the most robustly supported in the growth hormone secretagogue class.

FDA-approved Tesamorelin dosing (Egrifta/Egrifta SV) is 2 mg subcutaneous injection once daily in the morning. The lower-concentration Egrifta SV formulation (2 mg/2 mL) was introduced to reduce injection volume discomfort. Patients require 3–6 months to achieve full visceral fat reduction, which is assessed by CT abdomen in clinical trials. Treatment is continued as long as the benefit is maintained—visceral fat returns to baseline within 6 months of stopping. Dose adjustments are not required for renal impairment but it is contraindicated in pituitary disease that prevents GH response.

A 2018 JAMA Neurology randomized controlled trial (N=152) administered Tesamorelin to cognitively intact adults aged 60–85 for 20 weeks. Tesamorelin-treated participants showed preserved functional MRI connectivity in the default mode network (associated with memory function) and significantly better performance on verbal memory tasks compared to placebo. IGF-1 elevation mediated some of the cognitive effects. These findings are significant because they suggest GH/IGF-1 axis restoration may protect against age-related cognitive decline—a potential application of GHRH analogs extending well beyond body composition. Longer-term studies are needed.

Beyond visceral fat reduction, clinical trials document meaningful improvements in the lipid profiles of HIV-lipodystrophy patients treated with Tesamorelin: triglycerides reduce by approximately 15–20%, total cholesterol improves, and LDL/HDL ratio improves in subjects with baseline dyslipidemia. These improvements are consistent with visceral fat reduction (visceral fat is a major driver of dyslipidemia) and with the direct lipolytic effects of GH on lipid metabolism. The lipid improvements were maintained over 52-week extension studies. IGF-1 normalization may also contribute through its direct metabolic effects on hepatic lipid processing.